Early access
Sign in
Taking people in BelgiumPhase 1/2

A PET scan using a radioactive tracer to assess multiple myeloma

Tests a radioactive imaging tracer scan in adults with multiple myeloma.

Key facts

Who runs it
University Of Antwerp
Where
Edegem, Gent, and Leuven, BelgiumSee the 3 sitesAlso in 1 other country, 1 site
Registry title
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
Status
Recruiting
Phase
Phase 1/2
People taking part
90 people, planned
Started
20 Sept 2024
Planned end
31 Dec 2025
Type of study
Interventional
Record updated
2 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed multiple myeloma who are planned for induction chemotherapy followed by a stem-cell transplant (ASCT). It tests a [68Ga]Ga-PentixaFor PET scan.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Newly diagnosed multiple myeloma by current IMWG criteria, scheduled for induction chemotherapy followed by ASCT. WHO performance status 0-2; above 2 may be allowed if fit for intensive chemotherapy in the physician's opinion. Life expectancy over 12 months.
Earlier treatment
No induction chemotherapy yet: the [68Ga]Ga-PentixaFor PET/CT must be scheduled before it starts.
Biomarker or test result
A baseline 18F-FDG PET/CT scan is needed. The [68Ga]Ga-PentixaFor scan must come at most 14 days from the 18F-FDG scan.

Main reasons for not taking part

  • A condition that may affect following the study, such as severe claustrophobia or not being able to lie still for 30 minutes
  • Another cancer, except non-melanoma skin cancer, carcinoma in situ of the cervix, or a cancer treated and in remission for more than 5 years
  • Pregnant or breastfeeding
  • Refusal or inability to give written informed consent

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Transplant-eligible newly diagnosed multiple myeloma based on current IMWG criteria and scheduled for induction chemotherapy followed by ASCT
  • Baseline 18F-FDG PET/CT scan
  • WHO performance status 0-2 (WHO > 2 can be allowed if the patient is fit for intensive chemotherapy based on the opinion of the physician)
  • 18 years of older
  • Signed informed consent
  • Life expectancy > 12 months, based on clinical judgement
  • Baseline [68Ga]Ga-PentixaFor PET/CT should be scheduled before starting induction chemotherapy
  • An interval of maximum 14 days is allowed between the 18F-FDG and [68Ga]Ga-PentixaFor PET/CT scans (Specific for this study)

Who cannot take part

  • History of concomitant presence of any other malignancy, except for: non-melanoma skin cancer, carcinoma in situ of the cervix, or any other effectively treated malignancy that has been in remission for >5 years or that is highly likely to be cured at the time of enrollment
  • Any physical or physiological condition that may affect adherence to the study protocol, e.g severe claustrophobia or the inability to lie still for 30 minutes
  • Pregnant or breastfeeding
  • Refusal or inability to provide written informed consent

Where in Belgium

Also in 1 other country, 1 site

  • Antwerp University HospitalEdegem, BelgiumTaking people
  • Universitair Ziekenhuis GentGent, BelgiumTaking people
  • UZ LeuvenLeuven, BelgiumTaking people

About the trial

What the trial wants to find out

To evaluate the proportion of false negative (FN) PET results for [68Ga]Ga-PentixaFor PET/AC-CT at baseline.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
Plain-language title
A PET scan using a radioactive tracer to assess multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
2 September 2026